Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease, nephrology and transplantation, with a track record of advancing programs from early development through Phase 3 and regulatory approval. Dr. Dinavahi most recently served as Senior Vice President, Chief Medical Officer at Atara Biotherapeutics.

"I am delighted to welcome Rajani as our new Chief Medical Officer. She brings a rare combination of scientific rigor, clinical expertise and proven leadership in advancing innovative therapies from development to patients," said Mike Raab, president and chief executive officer of Ardelyx. "As we enter an important phase of growth and execution, Rajani's experience and vision will be instrumental in strengthening our pipeline, deepening our medical capabilities, and ensuring we continue to deliver meaningful outcomes for patients. I look forward to partnering closely with her as we build on our momentum and shape the next chapter of our company."

"I am thrilled to join Ardelyx at such a pivotal time in its evolution," said Dr. Dinavahi. "The company's commitment to advancing innovative therapies and its focus on patients strongly align with my own values and experience. I've been deeply impressed by the strength of the science, the dedication of the team and the opportunity to meaningfully impact patients' lives. I look forward to working alongside this talented organization to advance the pipeline, build on the company's momentum and help deliver important new medicines to patients who need them."

As Chief Medical Officer at Atara Biotherapeutics, Dr. Dinavahi's responsibilities spanned leading pre-clinical and translational sciences through global development and medical affairs of their lead T-cell directed therapy asset and allo-CART program. Prior to becoming CMO, Dr. Dinavahi held senior leadership positions at Atara across clinical sciences, program team leadership and medical affairs, where she built and led global teams to deliver on the first allogeneic T-cell therapy to be approved and launched globally. Earlier, she spent seven years at Amgen, contributing to multiple global development programs and regulatory filings for products approved across the U.S., Europe and Japan.

Dr. Dinavahi began her career in academic medicine as an Assistant Professor of Medicine (Nephrology) at Mount Sinai School of Medicine and a principal investigator in transplant research. She is board-certified in Internal Medicine and Nephrology, a Fellow of the American Society of Nephrology, and has authored numerous scientific publications and presentations. She earned a Bachelor of Science and Doctor of Medicine from the University of Miami and completed her Internal Medicine residency and Nephrology fellowship training at Thomas Jefferson University Hospital, followed by a clinical transplant and post-doctoral fellowship focusing on translational immunology at Mount Sinai Hospital in New York City.

About Ardelyx
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company's pipeline includes the Phase 3 development of tenapanor for chronic idiopathic constipation, and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor Contact:
Lisa Caperelli
lcaperelli@ardelyx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ARDX
The Conversation (0)
Michael Gentile Announces Filing of Early Warning Report Related to Acquisition of Common Shares of Cascadia Minerals Ltd.

Michael Gentile Announces Filing of Early Warning Report Related to Acquisition of Common Shares of Cascadia Minerals Ltd.

Michael Gentile announces that he has filed an early warning report (the "Report") announcing the acquisition (the "Acquisition") of an aggregate of 6,840,476 common shares (each, a "Common Share") in the capital of Cascadia Minerals Ltd. (the "Company") in connection with the exercise of an... Keep Reading...
Los Andes Copper Announces Grant of DSUs

Los Andes Copper Announces Grant of DSUs

Los Andes Copper Ltd. (TSXV: LA,OTC:LSANF) (OTCQX: LSANF) ("Los Andes" or the "Company") announces that the Company has granted an aggregate of 1,944 deferred share units ("DSUs") to two directors of the Company, pursuant to the Company's deferred share unit plan (the "DSU Plan").Each DSU... Keep Reading...
Steadright Signs Facilitator Agreement To Negotiate Critical Minerals Deal In Morocco

Steadright Signs Facilitator Agreement To Negotiate Critical Minerals Deal In Morocco

(TheNewswire) Muskoka, Ontario November 19th, 2026 TheNewswire Steadright Critical Minerals Inc. (CSE: SCM) ("Steadright" or the "Company") is pleased to announce that it has entered into a Share Acquisition Facilitation and Funding Agreement dated November 13, 2026 (the "Agreement") with... Keep Reading...
Ni-Co Energy Reports 4.60 Metres at 0.59% Nickel at Kremer-2; Phase-One Drilling Advances Magmatic Sulphide Exploration Model

Ni-Co Energy Reports 4.60 Metres at 0.59% Nickel at Kremer-2; Phase-One Drilling Advances Magmatic Sulphide Exploration Model

Assay-confirmed shallow mineralization; Sulphide-bearing mafic rocks at depth; Spring 2027 drilling planned Ni-Co Energy Inc. (TSXV: NICE,OTC:NICLF) ("Ni-Co" or the "Company") reports results from the initial phase of its 2026 diamond drilling campaign at its 100%-owned Kremer... Keep Reading...
Metalsource Mining Inc.    Reports New Drill Holes, Bold Exploration Push at Historic Silver Mine

Metalsource Mining Inc. Reports New Drill Holes, Bold Exploration Push at Historic Silver Mine

Via MiningNewsWire — Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) today announces its placement in an editorial published by via MiningNewsWire ("MNW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a... Keep Reading...
Metalsource Mining Receives $1.38 Million from Eric Sprott Warrant Exercise as Silver Hill Gold-Silver Exploration Advances

Metalsource Mining Receives $1.38 Million from Eric Sprott Warrant Exercise as Silver Hill Gold-Silver Exploration Advances

Eric Sprott now holds approximately 19.9% of outstanding shares, as proceeds strengthen Metalsource's treasury to advance aggressive expansion drilling and larger stepouts investigating the potential scale of the Silver Hill polymetallic system in North Carolina.Metalsource Mining Inc. (CSE:... Keep Reading...

Interactive Chart

Latest Press Releases

Related News